Hugh Barrett

Professor, Associate Dean (Research), Chair, Animal Ethics Committees, BAgrSc La Trobe, PhD Adel.

  • The University of Western Australia (M720), 35 Stirling Highway,

    6009 Perth

    Australia

  • 6432 Citations
  • 44 h-Index
19992019
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Hugh has been a biomedical research fellow for much of his career, supported via the NIH, National Heart Foundation, NHMRC and industry. His research has focussed on lipid and lipoprotein metabolism combined with mathematical modelling, using compartment models. His research career began at the BakerIDI, moved to the University of Washington and more recently the University of Western Australia, where he was also the Associate Dean, Research in the Faculty of Health and Medical Sciences.

His research has contributed to understanding lipid and lipoprotein metabolism in a variety of human dyslipidemic states and under various interventions designed to reduce cardiovascular disease burden. Using tracer methodologies his research has described the mechanism of action of statins, fibrates, CETP inhibitors, new PPAR agonists and other lipid lowering agents on lipoprotein kinetics, primarily in subjects with the metabolic syndrome. In addition, his research and modelling of tracer data in human, animal and in vitro systems has provided insight into the pathways that are responsible for the regulation of lipid metabolism.

His present role is focussed on building research capacity, quality, output and outcomes in the Faculty of Medicine and Health at UNE.

Roles and responsibilities

2018 - Associate Dean (Research), Faculty of Medicine and Health, University of New England Australia

2018 - Adjunct Professor, School of Biomedical Sciences, University of Western Australia

Previous positions

1989-1991 Senior Fellow, Center for Bioengineering, University of Washington, Seattle

1991-1997 Research Assistant Professor of Bioengineering, University of Washington, Seattle

1996 -1998 Co-Director, Resource Facility for Kinetic Analysis

1997- 1999 Research Associate Professor of Bioengineering, University of Washington, Seattle

1998 Raine Visiting Professor, University Department of Medicine, University of Western Australia

1999 - 2006 Associate Professor, School of Medicine and Pharmacology, University of Western Australia

1999 - 2007 Affiliate Associate Professor, Department of Bioengineering, University of Washington, Seattle

2001 - 2018 Director, Lipoprotein Research Unit, School of Medicine and Pharmacology, University of Western Australia

2001 - 2011 Director, Biostatistics and Mathematical Modeling Unit, School of Medicine and Pharmacology, University of Western Australia

2002 - 2005 Career Development Fellow, National Heart Foundation of Australia

2005 - 2016 Senior Research Fellow, National Health & Medical Research Council

2005 - 2010 & 2014-2015 Director of Research, School of Medicine and Pharmacology

2006 - Professor in Systems Biology, School of Medicine and Pharmacology, University of Western Australia

2008 – 2016 Affiliate Professor, Department of Bioengineering, University of Washington, Seattle

2016 - Acting Associate Dean (Research) Faculty of Medicine, Dentistry and Health Sciences

2016-18 Chair, Animal Ethics Committees, University of Western Australia

2017-18 Professor in Systems Biology, School of Biomedical Sciences, University of Western Australia

2017-18 Associate Dean (Research), Faculty of Health and Medical Sciences, University of Western Australia

Industrial relevance

Design and analysis of lipoprotein metabolic studies to identify and quantitate metabolic pathways in basal states and following intervention. Past research projects with Pfizer, Sanofi Aventis, Merck and ongoing projects with Amgen, Regeneron and Esperion.

Research

Hugh’s research focus is on the development of mathematical models, using a systems biology approach, to describe the metabolic pathways of lipid and lipoprotein metabolism. As one of the authors of the SAAM program he uses complex compartmental models to describe lipid and lipoprotein metabolism within individuals. In addition, he is developing models using population kinetics, in collaboration with the Department of Bioengineering at the University of Washington, Seattle that use data sets from large numbers of individuals and permit the identification of new covariates that are associated with lipid and lipoprotein metabolism. In addition, Hugh has a number of research collaborations with other lipid groups and with research in non-lipid areas including hormone metabolism.

In addition to basic and clinical research, Hugh is working in the area of Physical Activity Challenges and ran, with David Glance, the UWA Challenge in 2015. The next challenge, the City of Perth Challenge starts in March 2016. Associated with each challenge is a research study that measures CVD risk markers and measures of health and wellbeing.

Keywords

  • Cardiovascular disease
  • Clinical metabolic research
  • Lipid metabolism
  • Lipoprotein metabolism
  • Mathematical modelling
  • Systems biology
  • Compartment models

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 14 Similar Profiles
Apolipoprotein B-100 Medicine & Life Sciences
Lipoproteins Medicine & Life Sciences
Apolipoproteins B Medicine & Life Sciences
VLDL Lipoproteins Medicine & Life Sciences
Triglycerides Medicine & Life Sciences
Metabolism Chemical Compounds
Apolipoprotein A-I Medicine & Life Sciences
Apolipoprotein B-48 Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2000 2019

Research Output 1999 2018

Blood Platelets
Exercise
Platelet Activation
Brachial Artery
Acute Coronary Syndrome

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient (LDLR+/− and LDLR−/−) Yucatan Miniature Pigs

Burke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Barrett, P. H. R., Newton, R. S., Pickering, J. G. & Huff, M. W., 15 Feb 2018, In : Arteriosclerosis, thrombosis, and vascular biology. 38, 5, p. 1178-1190

Research output: Contribution to journalArticle

Open Access
File
LDL Receptors
LDL Cholesterol
Atherosclerosis
Swine
Cholesterol
Open Access
Apolipoprotein B-48
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
Triglycerides
Apolipoprotein B-100

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

Watts, G. F., Chan, D. C., Somaratne, R., Wasserman, S. M., Scott, R., Marcovina, S. M. & Barrett, P. H. R., 14 Jul 2018, In : European Heart Journal. 39, 27, p. 2577-2585 9 p.

Research output: Contribution to journalArticle

Lipoprotein(a)
Apoprotein(a)
AMG 145
Proprotein Convertase 9
Apolipoproteins B
1 Citations
Apoprotein(a)
Lipoprotein(a)
Carotid Stenosis
Kringles
Coronary Artery Disease